



(12) Translation of
European patent specification

(11) NO/EP 3095856 B1

NORWAY

(19) NO
(51) Int Cl.
C12N 5/02 (2006.01)
C12M 1/12 (2006.01)
C12N 5/071 (2010.01)
C12N 5/078 (2010.01)

Norwegian Industrial Property Office

(21)	Translation Published	2020.01.20
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.08.14
(86)	European Application Nr.	16170752.6
(86)	European Filing Date	2009.09.16
(87)	The European Application's Publication Date	2016.11.23
(30)	Priority	2008.09.16, US, 97490 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2334785, 2009.09.16
(73)	Proprietor	Mayo Foundation for Medical Education and Research, 200 First Street S.W., Rochester, MN 55905, USA
(72)	Inventor	DIETZ, Allan B., 1301 3rd Street SW, Chatfield, MN 55923, USA BUTLER, Greg W., 6121 25th Avenue NW, Rochester, MN 55901, USA GUSTAFSON, Michael P., 4712 Canterbury Ct NW, Rochester, MN 55901, USA

(54)	Title	COMPOSITIONS CONTAINING PLATELET CONTENTS
(56)	References Cited:	WO-A1-89/10398 RUBEN CRESPO-DIAZ ET AL: "Platelet Lysate Consisting of a Natural Repair Proteome Supports Human Mesenchymal Stem Cell Proliferation and Chromosomal Stability", CELL TRANSPLANTATION, vol. 20, no. 6, 1 June 2011 (2011-06-01), pages 797-811, XP055042115, ISSN: 0963-6897, DOI: 10.3727/096368910X543376 LUCARELLI E ET AL: "Platelet-derived growth factors enhance proliferation of human stromal stem cells", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 24, no. 18, 1 August 2003 (2003-08-01), pages 3095-3100, XP004441790, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(03)00114-5 CAPELLI C ET AL: "Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts", BONE MARROW TRANSPLANTATION, NATURE PUBLISHING GROUP, GB, vol. 40, no. 8, 1 October 2007 (2007-10-01), pages 785-791, XP002545732, ISSN: 0268-3369, DOI:

10.1038/SJ.BMT.1705798 [retrieved on 2007-08-06]

MARTINEAU I ET AL: "Effects of calcium and thrombin on growth factor release from platelet concentrates: Kinetics and regulation of endothelial cell proliferation", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 25, no. 18, 1 August 2004 (2004-08-01), pages 4489-4502, XP004497111, ISSN: 0142-9612, DOI:

10.1016/J.BIOMATERIALS.2003.11.013

DOUCET CHRISTELLE ET AL: "Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications", JOURNAL OF CELLULAR PHYSIOLOGY, WILEY SUBSCRIPTION SERVICES, INC, US, vol. 205, no. 2, 1 November 2005 (2005-11-01), pages 228-236, XP002454867, ISSN: 0021-9541, DOI: 10.1002/JCP.20391

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** Blodplatelysatsammensetning omfattende et filtrat fra et lysert blodplatepreparat som er sendt gjennom et filter på 0,45 µm og/eller 0,2 µm for anvendelse til sårheling, hvori filtratet omfatter mer enn 200 pg VEGF-polypeptid per ml.
- 10 **2.** Blodplatelysatsammensetningen for anvendelse ifølge krav 1, hvori sammensetningen er en spray, et lim eller en sutur.
- 3.** Blodplatelysatsammensetningen for anvendelse ifølge krav 1 eller krav 2, hvori såret er et diabetessår, en fistel eller et kutt.
- 15 **4.** Blodplatelysatsammensetningen for anvendelse ifølge et hvilket som helst av kravene 1 til 3, hvori sammensetningen ytterligere omfatter heparin.